MAPT and Alzheimer disease: For instance, fMRI-based BAGs were not found to be linked to the amount of amyloid or tau pathology in amyloid-positive, cognitively impaired individuals (44), nor in preclinical familial AD (45), suggesting non-AD pathologies may drive fMRI-based functional brain age acceleration, or the latter may be masked by compensatory mechanisms.